Indications |
Nasal Allergic rhinitis Adult: ≥12 yr: As 0.6% nasal spray: Instill 2 sprays into each nostril twice daily. Ophthalmic Allergic conjunctivitis Adult: As 0.1% solution: 1 or 2 drops in the affected eye(s) bid at an interval of 6-8 hr. Alternatively, as a 0.2% solution: 1 drop in the affected eye(s) once daily. Child: ≥3 yr: As 0.1% solution: 1 or 2 drops in the affected eye(s) bid at an interval of 6-8 hr. Alternatively, as a 0.2% solution: 1 drop in the affected eye(s) once daily. |
Contraindications |
Hypersensitivity. Ophthalmic: Children <3 yr. Nasal: Children <12 yr. |
Warnings / Precautions |
Pregnancy, lactation. Ophthalmic: Remove contact lenses prior to eye admin. Reinsert soft contact lenses 10 min after admin. |
Adverse Reactions |
Ophthalmic: Headache; asthenia; cold syndrome; pharyngitis; rhinitis; sinusitis; dysgeusia; ocular burning or stinging; dry eye; foreign body sensation; hyperaemia; keratitis; lid oedema; ocular pruritus; blurred vision. Nasal: Bitter taste, nasal ulceration, epistaxis, drowsiness. |
Mechanism of Actions |
Olopatadine is a relatively selective histamine H1-receptor antagonist and inhibits the release of histamine from mast cells. It shares many of the pharmacologic effects of mast cell stabilisers. Absorption: Ophthalmic: Little systemic absorption. Distribution: Protein-binding: 55% Metabolism: Not extensively metabolised. Excretion: Via urine: 60-70 %, via faeces: 17 % |
Storage Conditions |
Nasal: Store at 4 to 25 °C. Ophthalmic: Store at 2-25°C. |
ATC Classification |
R01AC08 - olopatadine ; Belongs to the class of topical antiallergic preparations, excluding corticosteroids. Used as antiallergic agents. S01GX09 - olopatadine ; Belongs to the class of other ophthalmologic antiallergics. |
Storage |
Nasal: Store at 4 to 25 °C. Ophthalmic: Store at 2-25°C. |
Available As |
|
Olopatadine
Post Review about Olopatadine Click here to cancel reply.
Olopatadine Containing Brands
Olopatadine is used in following diseases
Drug - Drug Interactions of Olopatadine
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.